Howard G. Smith MD, AM on Instagram: "Moderna Has TWO CoVid Vaccines For 2025-2026 The new Moderna mRNA CoVid vaccine is named mNEXSPIKE; their original CoVid vaccine was named SPIKEVAX. This second generation mRNA CoVid vaccine yields a stronger and longer-lasting antibody response to the virus. By targeting specific viral spike proteins rather than all proteins contained in the spike itself, the robust antibody response lasts 6 months or longer rather than the usual 4 to 5 month duration. Due to its novelty, mNEXSPIKE has been approved only for adults 65 years of age and older as well as those 12 years through 64 years of age with complicating medical issues that place them at high risk for severe COVID-19. Not all pharmacies are stocking mNEXSPIKE, so, if you are eligible, check with yours. The second Moderna CoVid vaccine is the updated SPIKEVAX. This vaccine as well as the mNEXSPIKE produce antibodies against the JN.1 subvariant of the Omicron CoVid variant. This vaccine is approved for all children 6 months through 17 years of age. It is also approved for all adults 18 through 64 years of age. Officially the recipients in this age group must have at least one underlying medical issue, but all of the medical specialty societies are recommending any of the CoVid vaccines for anyone in this age group. Those eligible for the newer and robust $ mNEXSPIKE vaccine but received the $ SPIKEVAX vaccine, Pfizer’s mRNA vaccines, or Novavax purified protein vaccines, $ can receive it 2 or more months following their last vaccination. Since these latest versions of the $ classic CoVid vaccines protect optimally for about 4 months, you could seek the mNEXSPIKE after that time. https://www.modernatx.com/en-US/media-center/all-media/blogs/introducing-mnexspike-modernas-new-covid-19-vaccine https://www.modernatx.com/en-US/products/mnexspike https://www.modernatx.com/en-US/products/spikevax #moderna #CoVid #vaccine #spikevax #mnexspike"

Moderna's new COVID-19 vaccines, mNEXSPIKE and SPIKEVAX, are changing the game. Learn about their approval, benefits, and who's eligible for each.